Research peptidescjc-1295 dosage

CJC-1295 Dosage Chart and Calculator: Protocol and Trial Data

CJC-1295 dosage chart: units per dose by vial size for the 100-300 mcg no-DAC common protocol, a calculator, and the only human trial data (with-DAC form).

Written bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

Published September 27, 2026

The short version

CJC-1295 has no approved dose because it has no approved product, and the name covers two different molecules. Clinic and vendor guides most often describe 100-300 mcg of the no-DAC form by subcutaneous injection once daily, five days a week, for 8-16 weeks. That is common practice, not a dose any trial or regulator has established. The only published trial data is for the with-DAC form: single or repeated doses of 30 or 60 micrograms per kilogram.

Common practice is 100-300 mcg of the no-DAC form, subcutaneous, once daily, 5 days on and 2 off. It is not trial-established.
The only published human trial data is for the with-DAC form: 30 or 60 mcg/kg, subcutaneous, in a small trial.
That trial used single doses in one arm and 2-3 weekly or biweekly doses in another, over 28-49 days total.
Reconstitution and injection-volume math belongs on a calculator, not a guess.

CJC-1295 has no approved dose, because it has no approved product, and the name covers two different molecules with different evidence. This page reports what the one published human trial used for the long-acting, with-DAC form. It is not a recommendation. For the full with-DAC/without-DAC distinction, see the main CJC-1295 guide.

US legal status - Research use only

CJC-1295 has no FDA-approved product, in either form, and no approved indication or dose. Development reached Phase 2 and was discontinued.

AU legal status - Not on the ARTG

Schedule 4 of the Poisons Standard and named under Appendix D - prescription only, and not on the ARTG.

Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.

CJC-1295 dosage: the common protocol

Clinic and vendor dosing guides most often describe 100-300 mcg of the no-DAC form (mod GRF 1-29) by subcutaneous injection once daily, five days a week. Cycles run 8-16 weeks with a 4-6 week break between them. This is common practice, not a dose any trial or regulator has established.

Common protocol

What is commonly used, not a dose established in trials. No regulator has set a dose for CJC-1295.

Dose per administration: 100-300 mcg
How often: once daily, 5 days a week (5 days on, 2 off), usually the no-DAC form
Route: Subcutaneous injection
Cycle length: 8-16 weeks
Break between cycles: 4-6 weeks
Common vial size: 5 mg
Timing: Before bed, on an empty stomach (at least two hours after the last meal).
Commonly paired with: Ipamorelin, 5-Amino-1MQ, AOD-9604, BPC-157

Sources describe the no-DAC form (mod GRF 1-29) dosed daily; the longer-acting with-DAC form is dosed roughly weekly at higher per-injection amounts, but that variant was not what the sourced daily protocols describe.

Plan a cycle in the protocol builder or work out injection volume in the dosage calculator.

The common CJC-1295 dose is 100-300 mcg, once daily, 5 days a week (5 days on, 2 off), usually the no-DAC form. From a 5 mg vial mixed with 2 mL of bacteriostatic water, 200 mcg is 8 units (0.08 mL) on a U-100 insulin syringe.

CJC-1295 5 mg vial: units per dose

Full 5 mg vial page: mixing, doses per vial, how long it lasts →

Water added	Concentration	1 unit =	100 mcg	200 mcg	300 mcg
1 mL	5 mg/mL	50 mcg	2 units	4 units	6 units
2 mL	2.5 mg/mL	25 mcg	4 units	8 units	12 units
3 mL	1.67 mg/mL	16.67 mcg	6 units	12 units	18 units

CJC-1295 10 mg vial: units per dose

Full 10 mg vial page: mixing, doses per vial, how long it lasts →

Water added	Concentration	1 unit =	100 mcg	200 mcg	300 mcg
1 mL	10 mg/mL	100 mcg	1 unit	2 units	3 units
2 mL	5 mg/mL	50 mcg	2 units	4 units	6 units
3 mL	3.33 mg/mL	33.33 mcg	3 units	6 units	9 units

All CJC-1295 vial sizes: 5 mg · 10 mg

Units are on a standard U-100 insulin syringe (100 units = 1 mL), rounded to the nearest half unit - half-unit marks are on 0.3 mL syringes. Water volumes are examples: more water means more units per dose, not more doses per vial. For any other vial or dose, use the calculator below.

How many 5 mg vials a cycle takes

Scenario	Dose	Doses a week	Weeks	Total	5 mg vials
Low end of the common protocol	100 mcg	5	8	4 mg	1
High end of the common protocol	300 mcg	5	16	24 mg	5

Whole vials, rounded up. Plan a cycle with your own numbers in the protocol builder. Keep mixed vials cold and use them within the window in how long reconstituted peptides last; where to inject: subcutaneous injection sites.

CJC-1295 doses used in human studies (with-DAC form only)

A randomised, placebo-controlled trial in healthy adults aged 21-61 Teichman 2006 - Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805., in the references below tested the with-DAC, long-acting form of CJC-1295. It had two parts:

Part	Dose	Schedule	Duration
Ascending single-dose	One of four doses, 30 or 60 mcg/kg among them	Single subcutaneous injection	Followed for 28 days
Repeat-dose	30 or 60 mcg/kg	2-3 subcutaneous injections, spaced weekly or every two weeks	Followed for 49 days

A single injection produced dose-dependent increases in growth hormone for 6 or more days and in IGF-I for 9-11 days. Repeat dosing kept IGF-I above baseline for up to 28 days. The paper describes the 30 or 60 mcg/kg doses as safe and “relatively well tolerated,” with no serious adverse reactions reported. That is what this trial measured in healthy volunteers under clinical monitoring, not a dose this page recommends for anyone else.

The without-DAC form: no published human dosing study

CJC-1295 without DAC (sold as “mod GRF 1-29”) lacks the albumin-binding linker entirely. I could not find a peer-reviewed human pharmacokinetic or dosing study for it, so no trial has established a dose. The common protocol above reflects what clinic and vendor dosing guides describe as current practice for this form, with each source recorded and dated. It is not a trial finding. See the main guide for why treating the two forms as interchangeable is the most common factual error about this compound.

How to reconstitute CJC-1295

The injection volume for a target amount depends on how a specific vial was reconstituted (diluent volume and resulting concentration), which this page cannot know. The dosage calculator works through that arithmetic. It does not choose a dose.

What is not established

No approved dose exists, for either form, because no product has completed FDA review.
No dose has been proven safe or effective by any regulator. The figures above are one small trial’s own measurements, not a demonstrated general result.
The without-DAC form has no published human dosing trial, so the common protocol above is current practice from clinic and vendor guides, not a trial finding.
The with-DAC form’s community dosing figures (weekly, milligram-range) are a different, less-documented practice than the daily no-DAC protocol above, and are not covered by this page’s sourced protocol.

Who should not use it

No FDA-reviewed contraindication list exists, because no such review has happened. The published trial excluded participants with clinically significant medical, psychiatric or endocrine conditions, recent illness, and pregnancy. That shows who a monitored study considered eligible, not who is safe. Nobody should self-direct an unapproved research chemical around a current medical condition, medication or pregnancy.

CJC-1295 side effects and risks

The published trial reported no serious adverse reactions at the doses it tested. It was one small, short-term trial in healthy volunteers. It says nothing about long-term use, other doses, or the without-DAC form, for which no comparable human safety data exists. A vial bought outside the trial system carries no verified content, purity or actual concentration.

If you have taken more than intended, see CJC-1295 overdose: what to do.

CJC-1295 dosage calculator

Preset to a 5 mg vial and 100 mcg, the low end of the common protocol. Enter your own vial size, water and dose to get the syringe units to draw.

Your vial

Peptide in vial (mg)

Printed on the vial. There is no standard size - enter what yours says.

Bacteriostatic water added (mL)

This changes how much you draw - never how many doses the vial holds.

Desired dose (mcg)

Syringe scale

100 units per mL. 1 unit = 0.01 mL. This is what almost every insulin syringe sold is, in every barrel size.

Barrel size

Capacity only. A 1 mL U-100 syringe holds 100 units - the scale decides that, not the barrel.

Draw this much

4units

= 0.04 mL on a 1 mL U-100 syringe

Concentration: 2,500 mcg/mL
Exact volume: 0.04 mL
Dose you actually get: 100 mcg
Doses per vial(unaffected by water volume): 50

Where to buy CJC-1295 for research

Each vendor is checked against my vendor checklist.

1.Next Level PharmFeatured
5 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
- Takes card payment
$28.99as of 3 October 2026
View product →My Next Level Pharm review
2.BioEdge Research Labs
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
$78.00as of 3 October 2026
View product →My BioEdge Research Labs review

Compare every checked vendor for CJC-1295 →

See all vendors and how they compare →

Common questions

What is the usual CJC-1295 dose?

Clinic and vendor dosing guides most often describe 100-300 mcg of the no-DAC form (mod GRF 1-29), injected subcutaneously once daily, five days a week with two days off. It is typically taken before bed on an empty stomach, for an 8-16 week cycle with a 4-6 week break. That is common practice reported by clinic and vendor pages, not a dose established by any trial or regulator. The with-DAC form is dosed differently; see the next question.

What dose of CJC-1295 did the human trial use?

A published trial in healthy adults gave the with-DAC form of CJC-1295 as a subcutaneous injection at 30 or 60 micrograms per kilogram of body weight. One part used single ascending doses. A second part gave 2 to 3 doses spaced weekly or every two weeks. That is a trial design, not a recommended dose for anyone outside it.

Is there an FDA-approved CJC-1295 dose?

No. CJC-1295 has no FDA-approved product, in either the with-DAC or without-DAC form. It reached Phase 2 development and was discontinued. The trial dose figures on this page come from one published trial, not from FDA review or an approved label.

How often and for how long was CJC-1295 dosed in the trial?

The trial ran two designs: a single ascending-dose study with 28 days of follow-up, and a repeat-dose study giving 2-3 injections spaced weekly or biweekly, followed for 49 days total. Both were in healthy adults aged 21-61, not patients with any condition.

What about CJC-1295 without DAC (mod GRF 1-29)?

I could not find any published human pharmacokinetic or dosing study for the without-DAC form, so no trial has established a dose for it. Clinic and vendor dosing guides commonly describe 100-300 mcg by subcutaneous injection once daily, 5 days a week; see "The common protocol" above for the sourced detail. That is common practice, not a trial-established figure.

How do I work out reconstitution and injection volume?

The arithmetic depends on your vial's concentration and diluent volume, which this page cannot know. Use the dosage calculator to work through it for your vial and target amount. It does the calculation; it does not choose a dose.

What are the main risks?

The published trial reported no serious adverse reactions at the doses it tested. Beyond that small, short-term trial, there is no long-term human safety data for either form and no FDA-reviewed safety label. A vial bought outside the trial system has no verified content or purity.

When should I stop and get medical care?

Get emergency care (call 911 in the US) for signs of a severe allergic reaction: swelling of the face, lips, tongue or throat, or difficulty breathing. Do the same for any severe or rapidly worsening symptom after an injection. Call Poison Control at 1-800-222-1222 if you have taken an unknown or excessive amount of anything sold as CJC-1295. This page is not a substitute for a clinician who knows your history.

References (2 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.